Zurich Switzerland October 25 2013 Haselmeier Has Announced The Ce Mark Ofjuniorstarreg By Sanofi Juniorstarreg Is A New Easytouse Halfunit Insulin Reusable Pen Thatcan Be Used With Lantusreg Insulin Glargine Apidrareg Insulin Glulisine Or Insumanregrecombinant Human Insulin Developed And Manufactured By Haselmeier Juniorstarreg Is Alight Weight Reusable Pen With A Large Dose Display Singlestep Dial Back Without Insulin Leakageand Delivers From 1 To 30 Units Per Injectionldquohaselmeier Is Proud To Partner With Sanofi On This Important Program To Develop Andmanufacture Juniorstarreg And We Look Forward To Continuing Our Business Relationship In Thefuturerdquo Said Freacutedeacuteric Gabriel General Manager Of Haselmeierdirector Project Management At Haselmeier Sandra De Haan Adds That Ldquothe Excellentcooperation Between Sanofi And Haselmeier Project Teams Ensured Announcement To Thediabetes Community At The Recent Easd Congressrdquohalfunit Dose Increment Pens Provide Flexibility To Achieve Target Insulin Doses Especially Inyoung Patients With Diabetes Juniorstarreg Has Been Tested By People With Type 1 Diabetes 6to 18 Years Old Parents And Nurses In A Noncomparative Survey With 167 Insulin Pen Usersfrom Five European Countries1middot 81 Of Patientsparents And 86 Of Nurses Agreed It Is Easy To Carry On A Daily Basisdue Of Its Light Weight 34 Gramsmiddot 98 Of Patientsparents And 94 Of Nurses Agreed It Is Easy To Read Due To Its Largedose Display And Legible Numbersmiddot Additionally 91 Of Patientsparents And 89 Of Nurses Agreed That The Dialling Backwas Easy Due To Its Singlestep Dial Back Without Insulin Leakagemiddot Overall 93 Of Survey Participants Agreed On Its Ease Of Usejuniorstarreg Meets The New Iso 1160812012 Standard And Passed All Requirements Forrobustness And Dose Accuracy It Is Offered In Three Different Colors Blue Red And Silver Forflexibility And Insulin Differentiationjuniorstarreg Is Expected To Be Available In Europe And Canada Throughout 2014references1 Klonoff D Et Al Evaluation Of The Juniorstarreg Halfunit Insulin Pen In Young People Withtype 1 Diabetes User Perspectives European Endocrinology 2013 92825about Sanofisanofi A Global And Diversified Healthcare Leader Discovers Develops And Distributestherapeutic Solutions Focused On Patientsrsquo Needs Sanofi Has Core Strengths In The Field Ofhealthcare With Seven Growth Platforms Diabetes Solutions Human Vaccines Innovative Drugsconsumer Healthcare Emerging Markets Animal Health And The New Genzyme Sanofi Is Listedin Paris Euronext San And In New York Nyse Snyabout Haselmeierhaselmeier Is A Leading Designer And Manufacturer Of Pen And Autoinjection Systems Thecompanyrsquos Devices Feature Unique Function Design And Technology And Are Marketed By Leadingpharmaceutical And Biotechnology Companies Around The Worldfor More Information Please Visit Wwwhaselmeiercomcontacthaselmeier Gmbhdufourstrasse 328008 Zuumlrichswitzerlandnadia Di Seclitel 41 44 250 58 50nseclihaselmeiercomnbspnbsp
